PL2575865T3 - Kompozycja farmaceutyczna obejmująca AVE0010 i insulinę glargine - Google Patents

Kompozycja farmaceutyczna obejmująca AVE0010 i insulinę glargine

Info

Publication number
PL2575865T3
PL2575865T3 PL11723919T PL11723919T PL2575865T3 PL 2575865 T3 PL2575865 T3 PL 2575865T3 PL 11723919 T PL11723919 T PL 11723919T PL 11723919 T PL11723919 T PL 11723919T PL 2575865 T3 PL2575865 T3 PL 2575865T3
Authority
PL
Poland
Prior art keywords
ave0010
pharmaceutical composition
insulin glargine
glargine
insulin
Prior art date
Application number
PL11723919T
Other languages
English (en)
Inventor
Reinhard Becker
Gerrit Hauck
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PL2575865T3 publication Critical patent/PL2575865T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL11723919T 2010-05-28 2011-05-27 Kompozycja farmaceutyczna obejmująca AVE0010 i insulinę glargine PL2575865T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10164368A EP2389945A1 (en) 2010-05-28 2010-05-28 Pharmaceutical composition comprising AVE0010 and insulin glargine
EP11723919.4A EP2575865B1 (en) 2010-05-28 2011-05-27 Pharmaceutical Composition Comprising AVE0010 and Insulin Glargine
PCT/EP2011/058764 WO2011147980A1 (en) 2010-05-28 2011-05-27 Pharmaceutical composition comprising ave0010 and insulin glargine

Publications (1)

Publication Number Publication Date
PL2575865T3 true PL2575865T3 (pl) 2015-06-30

Family

ID=42773054

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11723919T PL2575865T3 (pl) 2010-05-28 2011-05-27 Kompozycja farmaceutyczna obejmująca AVE0010 i insulinę glargine

Country Status (9)

Country Link
US (1) US20130079279A1 (pl)
EP (4) EP2389945A1 (pl)
AR (1) AR081254A1 (pl)
DK (1) DK2575865T3 (pl)
ES (1) ES2532994T3 (pl)
HU (1) HUE024486T2 (pl)
PL (1) PL2575865T3 (pl)
TW (1) TW201201832A (pl)
WO (1) WO2011147980A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE519780T1 (de) 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
MX344293B (es) 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
PT2498802E (pt) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
MX2014001190A (es) 2011-08-10 2014-05-12 Adocia Solucion inyectable de al menos insulina basal.
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN107583039A (zh) 2012-01-09 2018-01-16 阿道恰公司 Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
FR3001896B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001895B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
CA2907848A1 (en) * 2013-04-03 2014-10-09 Sanofi Treatment of diabetes mellitus by long-acting formulations of insulins
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
CA2915413A1 (en) * 2013-06-17 2014-12-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
CN105899190B (zh) 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015170286A2 (en) * 2014-05-08 2015-11-12 Biolingus Ip Llc Modulation of blood glucose levels
LT3229828T (lt) * 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulino glargino/liksisenatido fiksuoto santykio kompozicija
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EA039114B1 (ru) * 2015-11-10 2021-12-06 Санофи-Авентис Дойчланд Гмбх Применение композиции с постоянным соотношением инсулин гларгин/ликсисенатид для лечения сахарного диабета 2 типа
WO2018055539A1 (en) * 2016-09-22 2018-03-29 Wockhardt Limited Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN117558435B (zh) * 2024-01-11 2024-03-19 四川省医学科学院·四川省人民医院 一种基于bcm设备的远程透析指导系统

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
HUE064811T2 (hu) * 2005-08-19 2024-04-28 Amylin Pharmaceuticals Llc Extendin diabétesz kezelésében és testtömeg csökkentésében történõ alkalmazásra
DE102008053048A1 (de) * 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten

Also Published As

Publication number Publication date
ES2532994T3 (es) 2015-04-06
EP2575865A1 (en) 2013-04-10
EP3300741A1 (en) 2018-04-04
WO2011147980A1 (en) 2011-12-01
EP2575865B1 (en) 2014-12-17
HUE024486T2 (en) 2016-01-28
EP2389945A1 (en) 2011-11-30
AR081254A1 (es) 2012-07-18
TW201201832A (en) 2012-01-16
DK2575865T3 (en) 2015-03-23
EP2898895A1 (en) 2015-07-29
US20130079279A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
PL2575865T3 (pl) Kompozycja farmaceutyczna obejmująca AVE0010 i insulinę glargine
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
HK1205690A1 (en) Pharmaceutical composition and administration thereof
EP2583703A4 (en) SELF-DAMAGING INSULIN SPRING WITH REPLACEABLE NEEDLE
HK1182496A1 (en) Insulin delivery device
HK1248592A1 (zh) 長效胰島素製劑
EP2598527A4 (en) RECOMBINANT EXPRESSED INSULIN POLYPEPTIDES AND APPLICATIONS THEREOF
ZA201301419B (en) Pharmaceutical composition and administrations thereof
GB201217611D0 (en) Immediate/delayed drug delivery
EP2563338A4 (en) HIGH SHEAR APPLICATION USED FOR DRUG DELIVERY
SG11201400293UA (en) Glycosylated polypeptide and drug composition containing said polypeptide
EP2523666A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES
EP2718283A4 (en) INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
ZA201409508B (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
EP2653181A4 (en) MOUTHPIECE TIP OF DRUG POWDER AND USE THEREOF
EP2586324A4 (en) TRANSDERMAL ADMINISTRATION BRACELET
IL223707A0 (en) N-hydroxyformamide derivative and medicament containing same
SG11201400289SA (en) Glycosylated polypeptide and drug composition containing said polypeptide
IL221501A (en) Medicinal product containing miramistine
EP2524698A4 (en) INSULIN PRODUCTION
HK1175456A1 (en) Anti-leishmania compound and anti-leishmania drug
HRP20150125T1 (hr) Farmaceutski oblik koji sadrži aspirin i bisoprolol
GB201012660D0 (en) Inhaler and formulation
EP2657236A4 (en) NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE
GB201112578D0 (en) Pharmaceutical preparation and use